Cook Pharmica to Add 80,000 SF in $80M Expansion
- Feb 06, 2008
Cook Pharmica, a contract biopharmaceutical manufacturer and wholly owned subsidiary of Cook Medical, will spend $80 million to add 80,000 square feet to its facility in Bloomington, Ind. When complete, the expansion will accommodate 200 new professional, hourly, and management employees. Plans call for the construction of four plant lines. Two will fill syringes and vials with biopharmaceuticals, while the other two finish and package the materials for shipment. Construction will begin at mid-year, with the new facilities coming on line in early 2010. “Our industry is seeing phenomenal growth,” Jerry Arthur, president of Cook Pharmica, told CPN today. “Four years ago, 35 percent of the inject-able drugs on the market were produced in biotech manufacturing processes. By 2012, 70 percent of this market will be biotech products. In other words, the industry will double in eight years. That’s what we’re preparing for with this expansion.” The advanced technology manufacturing capability and the necessary infrastructure explain the high $1,000 per-square-foot cost of the expansion. For instance, the filling lines will require a lyophilization or freeze-drying capacity of up to 250 square feet. The effort will continue a major Cook Medical expansion effort that includes Cook Urological in Spencer, Ind., as well as several overseas plants. In addition, a new Cook office and warehouse will open in Shanghai later this year. Cook Pharmica’s main campus can accommodate more than 600,000 square feet of additional expansion as demand for biotech inject-able products continues to grow. The parent company, Cook Medical, integrates device design, biopharma, gene and cell therapy, and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics.